London startup raises $60M for degraders aimed at Alzheimer’s protein tau

Oyster Therapeutics has raised $60 million to develop pills that destroy pathogenic forms of tau, a brain protein implicated in Alzheimer’s disease. The Series A-2 funding was led by life-science venture capital fund 4BIO Capital ...